These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 9918478

  • 1. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
    Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB.
    JAMA; 1999 Jan 20; 281(3):235-42. PubMed ID: 9918478
    [Abstract] [Full Text] [Related]

  • 2. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
    Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M.
    Lancet; 1998 Jul 18; 352(9123):167-72. PubMed ID: 9683204
    [Abstract] [Full Text] [Related]

  • 3. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N, James WP, Kopelman PG, Lean ME, Williams G.
    Int J Obes Relat Metab Disord; 2000 Mar 18; 24(3):306-13. PubMed ID: 10757623
    [Abstract] [Full Text] [Related]

  • 4. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
    Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ.
    Am J Clin Nutr; 1999 Jun 18; 69(6):1108-16. PubMed ID: 10357727
    [Abstract] [Full Text] [Related]

  • 5. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.
    Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjöström L.
    Arch Intern Med; 2000 May 08; 160(9):1321-6. PubMed ID: 10809036
    [Abstract] [Full Text] [Related]

  • 6. Treatment with orlistat reduces cardiovascular risk in obese patients.
    Zavoral JH.
    J Hypertens; 1998 Dec 08; 16(12 Pt 2):2013-7. PubMed ID: 9886891
    [Abstract] [Full Text] [Related]

  • 7. [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].
    Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar H, Krempf M, European Multicenter Orlistat Study Group.
    Ter Arkh; 2000 Dec 08; 72(8):50-4. PubMed ID: 11019429
    [Abstract] [Full Text] [Related]

  • 8. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group.
    Int J Obes Relat Metab Disord; 2001 Nov 08; 25(11):1713-21. PubMed ID: 11753595
    [Abstract] [Full Text] [Related]

  • 9. Orlistat in the long-term treatment of obesity in primary care settings.
    Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR.
    Arch Fam Med; 2000 Feb 08; 9(2):160-7. PubMed ID: 10693734
    [Abstract] [Full Text] [Related]

  • 10. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J.
    JAMA; 2005 Jun 15; 293(23):2873-83. PubMed ID: 15956632
    [Abstract] [Full Text] [Related]

  • 11. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.
    Diabetes Obes Metab; 2003 May 15; 5(3):180-8. PubMed ID: 12681025
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr 15; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 13. A one-year trial to assess the value of orlistat in the management of obesity.
    James WP, Avenell A, Broom J, Whitehead J.
    Int J Obes Relat Metab Disord; 1997 Jun 15; 21 Suppl 3():S24-30. PubMed ID: 9225173
    [Abstract] [Full Text] [Related]

  • 14. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z.
    Med Pregl; 1999 Jun 15; 52(9-10):323-33. PubMed ID: 10624380
    [Abstract] [Full Text] [Related]

  • 15. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension.
    Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I, orlistat and resistant hypertension investigators.
    J Hypertens; 2002 Nov 15; 20(11):2257-67. PubMed ID: 12409965
    [Abstract] [Full Text] [Related]

  • 16. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.
    Lindgärde F.
    J Intern Med; 2000 Sep 15; 248(3):245-54. PubMed ID: 10971792
    [Abstract] [Full Text] [Related]

  • 17. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
    Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J.
    Diabetes Care; 1998 Aug 15; 21(8):1288-94. PubMed ID: 9702435
    [Abstract] [Full Text] [Related]

  • 18. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov 15; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 19. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID.
    Diabetes Obes Metab; 2005 May 15; 7(3):254-62. PubMed ID: 15811142
    [Abstract] [Full Text] [Related]

  • 20. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns.
    Karhunen L, Franssila-Kallunki A, Rissanen P, Valve R, Kolehmainen M, Rissanen A, Uusitupa M.
    Int J Obes Relat Metab Disord; 2000 Dec 15; 24(12):1567-72. PubMed ID: 11126207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.